# Ion-Channel-Targeting Scorpion Recombinant Toxin as Novel Therapeutic Agent for Breast Cancer

## TL;DR

This paper explores scorpion venom peptides as a new treatment for breast cancer by targeting ion channels, which could improve treatment effectiveness and reduce side effects.

## Contribution

The study introduces ion-channel-targeting scorpion venom peptides as a novel therapeutic strategy for breast cancer.

## Key findings

- Venom-derived peptides from Chihuahuanus coahuilae alter cancer cell homeostasis by changing ion fluxes.
- These peptides promote apoptosis and inhibit metastatic traits in breast cancer cells.
- The findings suggest potential for selective anticancer agents targeting ion channels.

## Abstract

Breast cancer remains the leading cause of cancer-related mortality among women worldwide, with limited therapeutic efficacy due to treatment resistance and adverse effects. Emerging evidence suggests that ion channels play crucial roles in tumor progression, regulating proliferation, apoptosis, migration, and metastasis. Voltage-gated potassium (Kv) and sodium (Nav) channels have been implicated in oncogenic signaling pathways. Scorpion venom peptides, known for their selective ion-channel-blocking properties, have demonstrated promising antineoplastic activity. This study explores the potential therapeutic applications of bioactive fractions derived from Chihuahuanus coahuilae, in breast cancer cell lines. Through chromatographic separation, mass spectrometry, and functional assays, we assess their effects on cell viability, proliferation, and ion channel modulation. Our preliminary data suggest that these venom-derived peptides interfere with cancer cell homeostasis by altering ion fluxes, promoting apoptosis, and inhibiting metastatic traits. These findings support the therapeutic potential of ion-channel-targeting peptides as selective anticancer agents. Further investigations into their molecular mechanisms may pave the way for novel, targeted therapies with improved efficacy and specificity for breast cancer treatment.